<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5F44D980-91F5-4741-B8D1-6E7FB9183303"><gtr:id>5F44D980-91F5-4741-B8D1-6E7FB9183303</gtr:id><gtr:name>Fudan University</gtr:name><gtr:address><gtr:line1>670 Guoshun Road</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/BECA2763-0902-40AA-8DB2-836A5731CF58"><gtr:id>BECA2763-0902-40AA-8DB2-836A5731CF58</gtr:id><gtr:name>Brunel University</gtr:name><gtr:department>Sch of Health Sciences and Social Care</gtr:department><gtr:address><gtr:line1>Brunel University</gtr:line1><gtr:line4>Uxbridge</gtr:line4><gtr:line5>Middlesex</gtr:line5><gtr:postCode>UB8 3PH</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/BECA2763-0902-40AA-8DB2-836A5731CF58"><gtr:id>BECA2763-0902-40AA-8DB2-836A5731CF58</gtr:id><gtr:name>Brunel University</gtr:name><gtr:address><gtr:line1>Brunel University</gtr:line1><gtr:line4>Uxbridge</gtr:line4><gtr:line5>Middlesex</gtr:line5><gtr:postCode>UB8 3PH</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5F44D980-91F5-4741-B8D1-6E7FB9183303"><gtr:id>5F44D980-91F5-4741-B8D1-6E7FB9183303</gtr:id><gtr:name>Fudan University</gtr:name><gtr:address><gtr:line1>670 Guoshun Road</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/4238642F-3B6A-4FC3-89CB-E4F14D8A9223"><gtr:id>4238642F-3B6A-4FC3-89CB-E4F14D8A9223</gtr:id><gtr:firstName>Suling</gtr:firstName><gtr:surname>Li</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/37045E22-5D00-442F-B7BB-168224234D53"><gtr:id>37045E22-5D00-442F-B7BB-168224234D53</gtr:id><gtr:firstName>Ping</gtr:firstName><gtr:surname>Wang</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0300520"><gtr:id>73ADE36F-7F38-478C-AFD2-49EDEA32C310</gtr:id><gtr:title>Induction of CTL immunoresponses to HIV-1 by peptide-edited microsomes</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0300520</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2008-03-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>191788</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Fudan University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:description>jiming zhang, professor</gtr:description><gtr:id>0DE8A5AD-834F-41C8-BC75-53E8B9FBF21D</gtr:id><gtr:impact>we have mainly worked on the HBV patient invitro study currently</gtr:impact><gtr:partnerContribution>HBV patient in vitro study currently</gtr:partnerContribution><gtr:piContribution>HBV vaccine development</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>vaccine development for HIV</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>64863B97-E7F9-4590-A83E-FD84DC8CD53B</gtr:id><gtr:impact>around 120 people from pharmaceutical company attended the meetings, mainly inteerested in the new technology of our microsome vaccine strategy.

some collaborations potential have been developed</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007,2009,2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>A vaccine composition comprising isolated inverted microsomes from an animal cell, or membrane fragments thereof, in association with an externally disposed peptide antigen and a protein of the Major Histocompatibility Complex (MHC).

2. A composition as claimed in claim 1, in which the microsome is from the endoplasmic reticulum of the cell.

3. A composition as claimed in claim 1, in which the protein of the MHC is from a heterologous source with respect to the cell from which the microsomes are obtained.

4. A composition as claimed in claim 1, in which the composition additionally comprises one or more co-stimulatory molecules.

5. A composition as claimed in claim 4, in which the co-stimulatory molecules are selected from B7 and IL-2.

6. A composition as claimed in claim 1, in which the antigen is from a viral, bacterial, yeast, fungal, or protozoan origin.

7. A composition as claimed in claim 1, in which the antigen is an auto-antigen.

8. A composition as claimed in claim 6, in which the antigen is of neoplastic cell or cell of a cancer tumour, or a normal self-protein.

9. A composition as claimed in claim 8, in which the neoplastic cell or cancer cell tumour is from a melanoma, lung adenocarcinoma, colon cancer, breast cancer or leukemia cell.</gtr:description><gtr:id>A8E9D4BF-ED8D-43C0-BB8B-FBA094F2B494</gtr:id><gtr:impact>Relevant collaboration have been promoted and established with relevant pharmaceutical company</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>HK1093014</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>microsme vaccine technology</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>technology needed for HIV vaccine</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>7DD56BA8-7DD2-4FAB-9F4E-EB453B3AB3B6</gtr:id><gtr:impact>More emphasize that the technology to induce T cell immunity is needed if we want to achieve vaccine in chronic infection diseases such as HIV</gtr:impact><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>IL2 supermicrosome vaccine</gtr:description><gtr:id>965B27A9-29DE-4FA9-8D85-775B5AFB1D5D</gtr:id><gtr:impact>will much improve the vaccine for HIV and cancer</gtr:impact><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>IL2 supermicrosome vaccine</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:yearDevCompleted>2008</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>IL2 super microsome</gtr:description><gtr:id>5D18F647-0A7E-497A-8E99-683480DC34C9</gtr:id><gtr:impact>vaccine technology</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>vaccine delivery system</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9283210D-63A1-4111-AC0E-A7679D73B665"><gtr:id>9283210D-63A1-4111-AC0E-A7679D73B665</gtr:id><gtr:title>Antigen-loaded ER microsomes from APC induce potent immune responses against viral infection.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/af180b4f4b4156430bd66f71279148fc"><gtr:id>af180b4f4b4156430bd66f71279148fc</gtr:id><gtr:otherNames>Sofra V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AB0C8031-7905-4CFB-8D0C-0E2B512756E1"><gtr:id>AB0C8031-7905-4CFB-8D0C-0E2B512756E1</gtr:id><gtr:title>MaXlab: a novel application for the cross comparison and integration of biological signatures from microarray studies.</gtr:title><gtr:parentPublicationTitle>In silico biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3daf204bbfa132c668ec672127b3216f"><gtr:id>3daf204bbfa132c668ec672127b3216f</gtr:id><gtr:otherNames>Khalid S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1386-6338</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5DF24F32-A55B-484F-A7F0-474E923DB8E8"><gtr:id>5DF24F32-A55B-484F-A7F0-474E923DB8E8</gtr:id><gtr:title>Modulation of antigen-specific T-cells as immune therapy for chronic infectious diseases and cancer.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b8a46f3752fd4026773cf1b531707cbf"><gtr:id>b8a46f3752fd4026773cf1b531707cbf</gtr:id><gtr:otherNames>Li S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/29B05278-2A96-4077-A78D-716BC3220BAA"><gtr:id>29B05278-2A96-4077-A78D-716BC3220BAA</gtr:id><gtr:title>IL-2-engineered nano-APC effectively activates viral antigen-mediated T cell responses from chronic hepatitis B virus-infected patients.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/23f3c52fe5d543eeac44c3179f5ecda0"><gtr:id>23f3c52fe5d543eeac44c3179f5ecda0</gtr:id><gtr:otherNames>Liu M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0300520</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>